Bionano Genomics (BNGO) Current Assets (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Current Assets data on file, last reported at $39.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 13.25% year-over-year to $39.0 million; the trailing twelve-month figure through Mar 2026 stood at $39.0 million (down 13.25% YoY), and the FY2025 full-year result was $45.4 million, up 14.93% from the prior year.
• Current Assets declined to $39.0 million in Q1 2026, from $45.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $242.4 million in Q1 2022 to a low of $39.0 million in Q1 2026.
• A 5-year average of $105.7 million and a median of $85.6 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets plunged 71.82% in 2024 and advanced 14.93% in 2025, its largest moves.
• Tracing BNGO's Current Assets over 5 years: stood at $157.3 million in 2022, then retreated by 10.92% to $140.1 million in 2023, then sank by 71.82% to $39.5 million in 2024, then advanced by 14.93% to $45.4 million in 2025, then declined by 14.13% to $39.0 million in 2026.
• Business Quant data shows BNGO's Current Assets at $39.0 million in Q1 2026, $45.4 million in Q4 2025, and $48.8 million in Q3 2025.